3. ⢠Global public health problem affects 300 million
people worldwide & expected to 552 million by 2030
⢠Global mortality is 5.1 million per year majority from
cardiovascular disease
(1 Death every 6 seconds)
⢠India has largest number of diabetics in the world.
25-40% of these develop End Stage Renal Disease.
⢠One of the most serious microvascular complication
of DM
⢠DN occur in T1DM, T2DM & other forms of Diabetes
5. ⢠Structural & Functional renal damage
manifested as clinically detected Albuminuria
in the presence of normal or abnormal GFR
⢠Triad:- Albuminuria
(>300mg/24h or >300mg/gm of creatinine)
HTN
Declining renal function (GFR)
9. Time (yrs) 0 5 20 30
Onset of
Diabetes
Onset of
Proteinuria
End Stage
Renal
Disease
Hypertension
OVERT NEPHROPATHY
Rising S Cr,
Decreasing GFR
INCIPIENT NEPHROPATHY
Hyperfiltration,
microalbuminuria,
rising blood pressure
PRECLINICAL
NEPHROPATHY
10.
11. Stage 1 (Early Diabetes)
⢠Hyperglycemia leads to increased kidney
filtration (Hyperfiltration)
⢠This is due to osmotic load and toxic effects of
high sugar levels on kidney cells
⢠Increased Glomerular Filtration Rate
(GFR >90ml/min) with enlarged kidneys
12. Stage 2 (Developing Diabetes)
⢠Clinically silent phase with continued hyperfiltration
and hypertrophy
⢠The GFR remains elevated or has returned to normal
(GFR 60-89ml/min) but glomerular damage has
progressed to significant microalbuminuria.
(30-300mg/24hr)
⢠Significant microalbuminuria will progress to end-
stage renal disease (ESRD).
⢠Therefore, all diabetes patients should be screened
for microalbuminuria on a routine basis.
13. Stage 3 (Overt Diabetes)
⢠Glomerular damage has progressed to clinical
albuminuria (>300mg/24h) with
GFR 30-59ml/min.
⢠Basement membrane thickening due to AGEP
(Advanced glycation end products)
⢠Urine is âDipstick positive"
⢠Hypertension typically develops during this
stage
14. Stage 4 (Late-stage Diabetes)
⢠Glomerular damage continues with increasing
amounts of protein albumin in the urine.
⢠The kidneys filtering ability has begun to
decline steadily and blood urea nitrogen(BUN)
and creatinine (Cr) has begun to increase.
⢠The glomerular filtration rate(GFR) decreases
further more with GFR 15-29ml/min.
⢠Almost all patients have hypertension at this
stage.
15. Stage 5 (ESRD or CKD)
⢠GFR has fallen to <15 ml/min and renal
replacement therapy required (hemodialysis,
peritoneal dialysis, kidney transplantation)
16. Luis-RodrĂguez D, MartĂnez-Castelao A, GĂłrriz JL, Ălvaro FD, Navarro-GonzĂĄlez JF. Pathophysiological role and
therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes 2012; 3(1): 7-18
18. Algorithm
Urine dipstick for protein
(a) Type 1 : 5 years afterdiagnosis
or earlier in the presence of other
cardiovascular risk factos
(b) Type 2 : at the time of diagnosis
NEGATIVE POSITIVE
(urine protein >300mg/l)
on 2 separate occasions (exclude
other causes e.g. UTI, CCF etc.)
Overt nephropathy
Quantify excretion rate
e.g. 24-hr urine protein
POSITIVE
Screen for microalbuminuria
on early morning spot urine
Retest twice in 3 â6 months (exclude
other causes e.g. UTI, CCF etc.)
NEGATIVE
If 2 of 3 tests are positive, diagnosis
of microalbuminuria is established
3-6 monthly follow-up of
microalbuminuria
Optimise glycaemic control
Strict BP control
ACEI/ARB
Stop smoking
Lifestyle modification
Treat hyperlipidaemia
Avoid excessive protein
intake
Monitor renal function
Monitor for other diabetic
endorgan damage
Yearly test
20. Microalbuminuria
⢠1st sign of nephropathy
⢠30-300mg/24hr Urine sample
⢠Powerful predictor of CVD and mortality
⢠Earlier 80% pts progress to clinical
albuminuria but due to multifactorial
intervention this has reduced to 20%.
21. Clinical Albuminuria
⢠Sensitive marker of CKD & CVD
⢠1st indicator of DN
⢠>300mg/24hr Urine sample
⢠Increase transglomerular pressure gradient
Loss of negative charged in GBM
Increase GBM pore size
⢠Majority pts progress to ESRD
28. Hypertension
Systemic BP reduction Intra-glomerular BP reduction
Anti-proteinuric effect
Blood pressure control
Beta blockers
Alpha -blockers
Vasodilators
ARB
ACEi
Preservation of other target organs Preservation of kidneys
Target BP <130/80 mmHg
29. Recommendations
⢠Nonpregnant patient with micro- or macroalbuminuria either ACE inhibitors
or ARBs should be used (A)
⢠In patients with type 1 diabetes, hypertension, and any degree of
albuminuria, ACE inhibitors have been shown to delay progression of
nephropathy (A)
⢠In patients with type 2 diabetes, hypertension, and
microalbuminuria, Both ACE inhibitors and ARBs have been
shown to delay progression to macroalbuminuria (A)
⢠Reduction of protein intake may improve measures of renal function (urine
albumin excretion rate, GFR)
⢠When ACE inhibitors, ARBs, or Diuretics are used, monitor serum creatinine,
potassium levels for development of acute kidney disease, hyperkalemia.
30. Anemia
⢠May occur when GFR < 50 % & almost always
present when GFR < 30 %
⢠Correct deficiencies
Iron, Folic acid, Vit B12, Pyridoxine
⢠Erythropoietin 75 - 150 IU/kg SC
â With Iron supplements
â Expensive therapy Rs. 8 - 10, 000 / month
â Hb % maintained at 11 â 12
â > 13 in pts with CAD
32. Fluid management
Many diabetics have nephrotic state and severe
edema and need salt & fluid restriction
600 - 800 ml / day
equal to UOP
⢠Severe edema
⢠Mild to moderate
⢠No edema UOP + insensible
losses